Avidity Biosciences has advanced a first antibody–oligonucleotide conjugate (AOC) into a phase I trial. Its AOC 1001 uses an antibody to carry an siRNA payload to muscle cells, for a rare muscle ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback